A VISIONaerie™ approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
Press Release
Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S.... Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of... Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of...STOCK Quote
NASDAQ: AERI
$22.91USD
Sep 19, 4:00 PM ET
VOLUME
869,158
DAY LOW/HIGH
$21.45/$23.04
52 - WEEK LOW/HIGH
$18.02/$63.20
